Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge

P L Dunn, C A Johnson, J M Styles, S S Pease, C J Dean, P L Dunn, C A Johnson, J M Styles, S S Pease, C J Dean

Abstract

Rat X rat hybridomas secreting monoclonal anti-idiotypic antibodies have been prepared from Hooded rats immunized with two tumour-reactive, syngeneic monoclonal antibodies 11/160 and M10/76 (specific, respectively, for the Hooded rat sarcomata HSN and MC24). The hybridomas were selected on the basis that the secreted antibodies competed with antigen for binding to the immunizing idiotype. One monoclonal anti-idiotype (HIM/1/230, gamma 2a isotype) that recognizes an antigen-binding site idiotope of antibody 11/160 has been found to substitute for antigen. Hooded rats vaccinated by three challenges with HIM/1/230 produce serum Ab3 that is indistinguishable in antigen specificity from the 11/160 Ab1, and show reduced tumour take following an i.v. challenge with 10(6) HSN cells. The response to vaccination with anti-idiotype was both qualitatively and quantitatively dependent on the mode of immunization. High titre 11/160-like Ab3 was generated only when the vaccine contained Freund's adjuvant, whereas resistance to tumour challenge was found only in animals vaccinated with anti-idiotype in the absence of adjuvant.

References

    1. Ann Immunol (Paris). 1974 Jan;125C(1-2):373-89
    1. J Exp Med. 1975 Jun 1;141(6):1411-26
    1. Fed Proc. 1977 Aug;36(9):2268-71
    1. Nature. 1979 Jan 11;277(5692):131-3
    1. Ann Immunol (Paris). 1979 Mar-Apr;130(2):281-91
    1. Br J Cancer. 1979 Nov;40(5):802-5
    1. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2209-13
    1. Immunology. 1980 Aug;40(4):683-6
    1. N Engl J Med. 1982 Mar 4;306(9):517-22
    1. Immunology. 1982 Nov;47(3):397-405
    1. Nature. 1983 Jun 16-22;303(5918):627-9
    1. Ann Immunol (Paris). 1983 Sep-Oct;134D(2):167-79
    1. Proc Natl Acad Sci U S A. 1984 Jan;81(1):216-9
    1. Proc Natl Acad Sci U S A. 1984 May;81(9):2864-7
    1. Cancer Res. 1984 Aug;44(8):3291-8
    1. Clin Exp Immunol. 1984 Aug;57(2):358-64
    1. J Exp Med. 1984 Oct 1;160(4):1001-11
    1. J Exp Med. 1984 Oct 1;160(4):1195-205
    1. J Immunol. 1985 Feb;134(2):1225-9
    1. J Exp Med. 1985 Jun 1;161(6):1432-49
    1. Cancer Res. 1960 Dec;20:1561-72
    1. Biochem J. 1963 Oct;89:114-23
    1. J Natl Cancer Inst. 1966 Jan;36(1):29-35
    1. J Immunol. 1977 Jun;118(6):2206-12

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する